Oakbrook Investments LLC decreased its stake in shares of Danaher Corporation (NYSE:DHR) by 19.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 32,700 shares of the conglomerate’s stock after selling 7,850 shares during the period. Oakbrook Investments LLC’s holdings in Danaher Corporation were worth $2,805,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in DHR. BlackRock Inc. boosted its holdings in shares of Danaher Corporation by 2,530.9% during the 1st quarter. BlackRock Inc. now owns 37,967,922 shares of the conglomerate’s stock worth $3,247,398,000 after buying an additional 36,524,795 shares during the period. Flossbach Von Storch AG boosted its holdings in shares of Danaher Corporation by 44.7% during the 2nd quarter. Flossbach Von Storch AG now owns 5,782,019 shares of the conglomerate’s stock worth $487,945,000 after buying an additional 1,785,810 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Danaher Corporation by 3.9% during the 1st quarter. Vanguard Group Inc. now owns 40,967,631 shares of the conglomerate’s stock worth $3,503,962,000 after buying an additional 1,530,015 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Danaher Corporation by 16,410.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,485,901 shares of the conglomerate’s stock worth $125,395,000 after buying an additional 1,476,901 shares during the period. Finally, Koch Industries Inc. boosted its holdings in shares of Danaher Corporation by 29,127.3% during the 2nd quarter. Koch Industries Inc. now owns 1,404,665 shares of the conglomerate’s stock worth $1,388,000 after buying an additional 1,399,859 shares during the period. 75.61% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/11/10/danaher-corporation-dhr-shares-sold-by-oakbrook-investments-llc.html.

In other news, insider William King sold 43,688 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $82.86, for a total value of $3,619,987.68. Following the completion of the transaction, the insider now directly owns 45,748 shares in the company, valued at approximately $3,790,679.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Donald J. Ehrlich sold 10,578 shares of the business’s stock in a transaction that occurred on Tuesday, October 24th. The shares were sold at an average price of $90.82, for a total transaction of $960,693.96. Following the completion of the transaction, the director now owns 104,621 shares of the company’s stock, valued at $9,501,679.22. The disclosure for this sale can be found here. Insiders sold a total of 279,628 shares of company stock valued at $25,304,394 over the last 90 days. Corporate insiders own 12.20% of the company’s stock.

Danaher Corporation (NYSE DHR) opened at $92.98 on Friday. The company has a market cap of $64,858.22, a P/E ratio of 23.97, a PEG ratio of 2.22 and a beta of 1.02. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42. Danaher Corporation has a 12-month low of $76.27 and a 12-month high of $93.36.

Danaher Corporation (NYSE:DHR) last issued its earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, beating the consensus estimate of $0.95 by $0.05. The company had revenue of $4.53 billion during the quarter, compared to analysts’ expectations of $4.47 billion. Danaher Corporation had a net margin of 13.36% and a return on equity of 11.29%. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.87 EPS. sell-side analysts predict that Danaher Corporation will post 3.99 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, October 27th. Stockholders of record on Friday, September 29th were given a $0.14 dividend. This represents a $0.56 annualized dividend and a dividend yield of 0.60%. The ex-dividend date was Thursday, September 28th. Danaher Corporation’s payout ratio is presently 16.52%.

Several analysts recently commented on the stock. Wells Fargo & Company assumed coverage on shares of Danaher Corporation in a report on Thursday, July 13th. They set a “market perform” rating and a $90.00 target price for the company. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $83.00 target price on shares of Danaher Corporation in a report on Tuesday, September 26th. Jefferies Group LLC reaffirmed a “buy” rating and set a $95.00 target price on shares of Danaher Corporation in a report on Friday, August 4th. BidaskClub downgraded shares of Danaher Corporation from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. Finally, Zacks Investment Research downgraded shares of Danaher Corporation from a “buy” rating to a “hold” rating in a report on Thursday, July 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Danaher Corporation currently has a consensus rating of “Buy” and a consensus price target of $93.31.

Danaher Corporation Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR).

Institutional Ownership by Quarter for Danaher Corporation (NYSE:DHR)

Receive News & Stock Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related stocks with our FREE daily email newsletter.